LOAd 713
Alternative Names: LOAd-713Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Lokon Pharma
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Immunologic cytotoxicity; Interleukin 6 receptor antagonists; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in Sweden (Parenteral)
- 15 Sep 2020 Preclinical trials in Cancer in Sweden (Parenteral), before September 2020 (Lokon Pharma pipeline, September 2020)